SUZHOU, China, April 19, 2020 /PRNewswire/ — Innovent Biologics, Inc. (”Innovent” or “the Company”) (HKEX: 1801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre™ (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Pemazyre is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR). Continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial(s).
The FDA approval was based on data from the FIGHT-202 study, a multi-center, open-label, single-arm study that evaluated Pemazyre as a treatment for adults with cholangiocarcinoma.
Here come the cures!
This may be why POTUS said he hated mosquitos yesterday:
Microsoft co-founder Bill Gates released a swarm of mosquitoes on an unsuspecting audience at a TED conference in 2009.
“There’s no reason only poor people should have the experience,” the billionaire said, before adding that the mosquitoes were not infectious.